ISO Factory API 99% Mildronate Dihydrate CAS 86426-17-7

• Powder: Yes
• Customized: Non-Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: TGYBIO20230529
• Product Name: Mildronate Dihydrate
• Specificcation: 99%
• Grade: Food Grade
• Shelf Life: 2 Years
• Storage: Cool Dry Place
• Shipping Time: Within 3-7 Working Days
• CAS: 86426-17-7
• Appearance: White Powder
• Transport Package: Foil Bag, Box, Drum
• Specification: 99% min
• Trademark: TGY
• Origin: China
• HS Code: 300440906
• Production Capacity: 1500kg/Month

Product Description

 

Product Name	Mildronate dihydrate
CAS No	86426-17-7
Molecular formula	C6H14N2O2.2H2O
Molecular weight	182.218
Grade	Phamaceutical Grade
Color	white powder
Purity	99%min
Shelf life	2 years

 a structural analogue of carnitine, competes to inhibit butaine hydroxylase, thereby inhibiting carnitine biosynthesis and directly inhibiting carnitine dependent fatty acid transport in mitochondria. Inhibition of carnitine biosynthesis reduces the intracellular concentration of free carnitine and prevents isoproterenol-induced acylcarnitine buildup.

Mildronate dihydrate (Meldoniu dihydrate) functions as a cardioprotective drug by cpmpetetively inhibiting BBOX1 and OCTN2. Mildronate (Meldoniu) exhibits IC50 values of 34-62 μM for human recombinant BBOX and an EC50 of 21 μM for human OCTN2. Mildronate (Meldoniu m) treatment-induced redirection of long-chain FA metabolism from mitochondria to peroxisomes[1].

The site of action is mitochondria, which improves myocardial energy metabolism at the cellular level. In view of the obvious difference between these drugs and other anti-myocardial ischemic drugs, they are also called cellular anti-ischemic drugs.
It is a structural analogue of carnitine and can compete to inhibit betaine butyrate hydroxylase, thereby inhibiting the biosynthesis of carnitine, and directly inhibiting the transport of carnitine-dependent fatty acids in the mitochondria. Inhibiting the biosynthesis of carnitine can reduce the concentration of free carnitine in cells and prevent the accumulation of acylcarnitine induced by isoproterenol. Therefore, the drug has a significant protective effect on the myocardium. While producing this protective effect, it has no significant impact on hemodynamic parameters, and there is no significant change in cardiac blood supply and cardiac oxygen consumption.